NVCR News and Press, NovoCure Limited From 04/20/21

Novocure (NASDAQ: NVCR) hasn't exactly been the kind of stock that fired up investors very much throughout most of 2021. That changed recently, though, with good news providing a huge catalyst for the stock. In this Motley Fool Live video recorded on April 14, 2021 , Motley ...

Insider buying increased significantly last week. Notable Insider Buys: Landec Corporation, Super League Gaming, Inc., Cyclo Therapeutics, Inc., Greenwich LifeSciences, Inc., and Hudson Global, Inc. Notable Insider Sells: Ulta Beauty, Inc., Facebook, Inc., Fidelity National Financ...

NovoCure continues to build out its product suite. The company is pivoting towards new indications which greatly expands the overall market. I think further expansion of its addressable market especially into non-small cell lung cancer should lead to an acquisition. For furt...

Novocure (NASDAQ: NVCR) has been on a tremendous run -- up 17 times over the last five years -- leaving many investors thinking that they missed the boat. But in investing, winners keep on winning. Recent news in the lung cancer treatment area for Novocure's Optune, a wearab...

Yesterday, Novocure's stock price made a huge jump of 50% because of an update of its LUNAR study. We look at the history of the company and the key people. Novocure already has 3 FDA approvals, 2 for glioblastoma and 1 for mesothelioma, but its total addressable market is much bi...

Yesterday, NovoCure ([[NVCR]] -5.2%) and its partner Zai Lab ([[ZLAB]] +2.7%) announced that a data monitoring committee (“DMC”) has recommended a reduced duration and sample size for its Phase 3 trial for Tumor Trial Fields (“TTF”) treatment in non-small cell...

Ongoing profitability a question mark at OrganigramCIBC analyst John Zamparo doesn't see Organigram Holdings (OGI) returning to positive EBIDTA soon, leading him to cut shares to underperformer and reducing his price target to C$3.25 from C$5.He says the COVID-19 pandemic will continue to imp...

Shares of Novocure (NASDAQ: NVCR) soared nearly 50% on Tuesday after the oncology company provided an update on a phase 3 trial of its experimental lung cancer treatment. An independent data monitoring committee (DMC) informed Novocure that an interim analysis for the study ...

Shares of NovoCure Limited (NASDAQ:NVCR) traded today at $218.12, eclipsing its 52-week high. Approximately 1.1 million shares have changed hands today, as compared to an average 30-day volume of 753,000 shares. NovoCure Ltd serves in the healthcare sector of the United States. Its busin...

Gainers: Mackinac Financial (MFNC) +56%.NovoCure (NVCR) +42%.vTv Therapeutics (VTVT) +42%.Digimarc (DMRC) +20%.PLBY Group (PLBY) +20%.Ballantyne Strong (BTN) +20%.Birks Group (BGI) +18%.Zai Lab (ZLAB) +16%.B. Riley Financial (RILY) +15%.Nam Tai Property (NTP) +14%.Losers: Brook...